Settling on an Increased NCI Budget

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

The final numbers are not in yet, but there is no doubt that Congress will fund the National Cancer Institute (NCI) at a considerably higher level than the $3.505 billion the Clinton administration asked for. That fiscal 2001 request was already nearly 6% above the actual 2000 budget.

The final numbers are not in yet, but there is no doubt that Congress will fund the National Cancer Institute (NCI) at a considerably higher level than the $3.505 billion the Clinton administration asked for. That fiscal 2001 request was already nearly 6% above the actual 2000 budget. The House approved $3.793 billion and the Senate went one better—to $3.804 billion. At the end of July, a House and Senate conference committee agreed to a compromise budget number for all the NIH institutes. Those numbers were not available at press time but were planned for release by October. It is safe to assume that the NCI budget will be somewhere between the House and Senate number. The size of the increase, of course, is good news. But the House and Senate enumerated a number of specific cancer research areas they expected to get more attention.Those “earmarks” can sometimes cause problems between cancer advocacy groups. The House, for example, lists 18 separate areas it expects the NCI to get a move on, including esophageal and stomach cancers, endometrial and cervical cancers, lung cancer screening, and urologic cancers.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content